Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Profit After Tax (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Profit After Tax data on record, last reported at -$10.2 million in Q3 2025.

  • For Q3 2025, Profit After Tax rose 74.74% year-over-year to -$10.2 million; the TTM value through Sep 2025 reached -$43.2 million, up 23.99%, while the annual FY2023 figure was -$27.0 million, 34.62% up from the prior year.
  • Profit After Tax reached -$10.2 million in Q3 2025 per CRVS's latest filing, down from -$8.0 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $15.2 million in Q1 2025 and bottomed at -$40.2 million in Q3 2024.
  • Average Profit After Tax over 4 years is -$8.7 million, with a median of -$7.9 million recorded in 2023.
  • Peak YoY movement for Profit After Tax: crashed 570.28% in 2024, then soared 366.5% in 2025.
  • A 4-year view of Profit After Tax shows it stood at -$9.8 million in 2022, then surged by 32.47% to -$6.6 million in 2023, then plummeted by 507.14% to -$40.2 million in 2024, then soared by 74.74% to -$10.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$10.2 million in Q3 2025, -$8.0 million in Q2 2025, and $15.2 million in Q1 2025.